CD19-directed CAR T cells could achieve complete remissions in up to 90% of patients with relapsed B-ALL [39], whereas durable anti-tumor responses were observed in only 26% of CLL patients infused with CAR T cells targeting CD19 [50]. This evidence concerns the gene CD19 and neoplasm.